erythromycin
Generic: ERYTHROMYCIN
Basic Information
Manufacturer
Asclemed USA, Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
OPHTHALMIC
FDA Set ID
6186510d-62ca-4083-9895-8d028d71b510
Indications & Usage
INDICATIONS AND USAGE: For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.
For prophylaxis of ophthalmia neonatorum due to N.
gonorrhoeae or C.
trachomatis .
The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.
gonorrheae is not established.
For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight.
Topical prophylaxis alone is inadequate for these infants.
For prophylaxis of ophthalmia neonatorum due to N.
gonorrhoeae or C.
trachomatis .
The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.
gonorrheae is not established.
For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight.
Topical prophylaxis alone is inadequate for these infants.
Adverse Reactions
ADVERSE REACTIONS: The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions.
To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .